Aim And Scope
Cancer refers to the abnormal growth of cell tissue. Tumors are usually divided into benign and
malignant. Malignant or cancerous tumors develop more rapidly.
They are not localized and are often fatal for the patient. A benign tumor is localised, develops slowly and does not
usually result in the patient’s death.
Oncology is the study of cancer and it deals with
diagnosis and treatment of different types of cancers Brain tumors,
melanoma, colorectal
cancer, pancreatic
cancer, hematological
cancer and so on.
Edelweiss
cancer Open Access is
interested in publishing research, review manuscripts covering all aspects
of cancer. We invite manuscripts which are novel and
highly innovative in detecting cancer of all forms. Clinical trial
studies, research on new therapeutic
agents, drugs and chemicals
and new concepts for detection and treatment of cancer. It is an open access journal maintained
by Edelweiss publications. The Journal follows rapid review process with
the Eminent Editorial Board. Edelweiss
cancer Open Access provides
a global open access platform for the upcoming researchers to globalize their
research.
Edelweiss Cancer Open Access is a peer reviewed
Journal, with rapid publication process. It covers the topics such as:
Cancer research, Mutations, Cancer epidemiology
and etiology, Cancer genomics and proteomics, Oncology Cancer and radiation
studies, Cancer genetic pathways, Cell cycle control, Apoptosis, DNA Repair,
Cancer and stem cells, Cancer therapeutics, Drugs used in Cancer treatment,
Oncology Cancer and radiation studies, DNA Bridges, Prevention studies and
education, Cancer cell biology, Melanoma, Non-coding RNA, Cell Proliferation and
not limited to above areas.
Current Key Issues
Giloblastoma, Cancer
Immunotherapy, TGF beta signaling in
cancer, Triple Negative
Breast, Chemotherapy, New Cancer Therapies, Myeloid Innate
Immunity.
Editorial Board
The Journal of cancer
consists of Editorial Board members from all over the world who help us in
rapid peer review process (4-6 weeks).
Ashok
Jain, Professor of Biology, Department
of Natural and Forensic Sciences, Albany State University, USA
Ben Franklin Warner, Professor, The University of Texas Health Science
Center, USA
Thereasa Cronan, Professor , Department
of Psychology, College of Sciences, San Diego State University, USA
Leukaemia
Leukaemia is a cancer in the blood forming tissues
where cancer cells circulate in the body and behave like healthy cells and they
imitate healthy cells, preventing their normal function. Carcinogenesis is a multistage process in which it causes
damage to the genetic material and changes the cell from normal function to
malignant.
Genetic
Defects
Genes are located within the cell structures
called chromosomes. Genes may undergo mutations and changes
regulatory system of the cell which usually leads to abnormal function of the
cell .A single geneticmutation will does not
cause cancer.
The two types of cancer genes Oncogenes, are cancer generating genes, upon activation
it causes distribution of cell tissue uncontrolled, regulation on the cells is
lost. Other is Anti-cancer genes or Tumors suppressor genes can induce cancer
due to the interruption/ ceases of their activity and causes damage to cell
function. But the human immune system can be able to repair the damage. If
immune system fail to work, damaged cells can start to divide uncontrollably
and leading to carcinogenesis. The majority of cancers are due to genetic
mutations are inherited in some cases. Environmental causes were not inherited
genetically such as pollution, tobacco, obesity, infections, radiations,
stress. Exposure to particular substances has chances causing specific types of
cancer. These substances are called carcinogens such as Tobacco smoke
causes lung cancer, larynx, head, neck, stomach, bladder,
esophagus and pancreas, kidney. The Edelweiss publications welcome original manuscripts related to
all cancer and its related aspects.
Heredity
The majority of cancers are inherited mutations
in the genes BRCA1 and BRCA2 with a more risk of breast cancer and
ovarian cancer, and hereditary nonpolyposis colorectal cancer (HNPCC or Lynch
syndrome). Editorial board ensures a rapid peer review process
helping Edelweiss Publications to run it successfully.
Infection
Oncoviruses includes human
papillomavirus (cervical
cancer), Epstein–Barr
virus (B-cell
lymphoproliferative disease and nasopharyngeal carcinoma), hepatitis B and hepatitis C viruses (hepatocellular carcinoma)
and human T-cell
leukemia virus-1 (T-cell
leukemias) .
Bacterial infection also increases the risk of
cancer, Helicobacter
pylori-induced gastric carcinoma.
Parasitic infections which induce cancer were Schistosoma haematobium (squamous cell carcinoma of
the bladder) and liver flukes, Opisthorchis viverrini and Clonorchis
sinensis (cholangiocarcinoma).
Manuscripts related to cerebellar degeneration shall be published in cancer journal.
You can submit us using the email id: editor@edelweisspublications.com
Radiation
Non-ionizing
ultraviolet radiations
causes non-melanoma skin cancers caused ultraviolet radiation, mostly from
sunlight. Ionizing radiations include medical imaging and radon gas. Ionizing radiation is not a particularly
strong mutagen but radiation is a more potent source of
cancer when combined with other cancer causing agents such as radon, tobacco
smoke and some more. More research done on Radiation induced cancer is welcome
we shall publish research/review/case reports in cancer journal.
Hormones
some hormones play a role in the development of cancer by promoting cell
proliferation Insulin growth factors and their binding proteins play a major
role in cancer cell proliferation, differentiation and apoptosis. The field of
oncology has three major areas surgical, medical and radiation. A surgical
oncologist performs certain types of biopsies to help diagnose cancer and
removes the tumor by surgery.
A medical oncologist treats cancer using chemotherapy and other medications, such as
targeted immunotherapy. A radiation oncologist treats cancer
using radiation
therapy More research done
on chemotherapy is welcome we shall publish research/review/case
reports in cancer journal. A hematologist treats with blood cancers, such as
leukemia, lymphoma, and myeloma. More research done on hematological malignancies is welcome we shall publish
research/review/case reports in cancer journal.
Genome
Editing Technology
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a family of DNA sequences in prokaryotes. It is one of the
defense mechanism in prokaryotes, these sequences contains snippets of DNA are
formed due to infection of viruses in bacteria and are used by the prokaryote
to detect and destroy DNA from similar viruses during subsequent
attacks and form the basis of a technology known as CRISPR/Cas9 that
effectively and specifically changes genes within organisms. Spacer is a short segment of DNA from previous
exposures to foreign DNA of a virus or plasmid. Small clusters of cas genes
are located next to CRISPR sequences. The following approach is an immune
therapy in which a patients own
blood cells will be removed and genetically altered using these technology. The
cancer treatment is designed to target myeloma, melanoma, and sarcomas. With the application of new gene editing
technologies in this field has great potential to improve human health. With
the Development of engineered site specific endonucleases like zinc finger nucleases (ZFNs), transcription activator like effector
nucleases (TALENs), and CRISPR/Cas9 has been revolutionizing genetic approaches
in biomedical research fields. These new tools have opened opportunities to
carry out targeted genome editing without the need for manipulating embryonic stem cells availability. This approach saves
time and cost. But CRISPR technology is considered far easier to use. The Edelweiss publications welcome original manuscripts related to
all advance molecular
genomic therapy on
cancer biology and its related aspects.
Few of the Articles Published in our journal
Examining
Chemotherapy-Related Cognitive Changes in Colorectal Cancer Patients: A
Feasibility Trial
Author(s): Marie-Rose
Dwek, Lorna Rixon, Alice Simon, Catherine Hurt, Stanton Newman
Introduction: Research suggests that chemotherapy may be related to decline in patients cognitive
functions. Objectives: To assess the feasibility and acceptability of
a multi-site study designed to examine the nature and extent of
chemotherapy-related cognitive changes in colorectal
cancer patients. Method: Data
was collected over 8 months using objective and self-reported measures of
cognitive functioning and self-reported quality of life, fatigue and mood
questionnaires. The assessment battery was administered pre- and
mid-chemotherapy treatment to a consecutive sample of colorectal cancer
patients across three London-based NHS Trusts. Participants included patients
who had undergone colorectal
surgery and were scheduled
to have adjuvant chemotherapy treatment, or no further cancer treatment. Main
outcome measures: Recruitment procedures, rate of recruitment, suitability
of exclusion/inclusion criteria, acceptability of data collection procedures
and the battery, and attrition rates. Results: From 1 April 2014 to 1
December 2014, 42 eligible participants were invited to take part in the trial.
Of the 17 that completed pre-chemotherapy assessments, only 1 withdrew at
follow-up due to reasons of ill health from disease recurrence. All
participants completed the entire battery and indicated that they found the
trial acceptable. Conclusions: What went wrong: Strained
researcher resources; loss of eligible participants to competing studies,
restrictive upper age limit. Possible solutions: Removal of upper age
limit, an increased dedicated research team to increase rate of recruitment.
The large multi-site study is feasible with suggested amendments and is
acceptable to patients and medical teams. Acceptability of trial to medical
teams is further evidenced by requests of collaboration from two additional
London based NHS Trusts. Lessons learned: This feasibility trial
provides evidence to other researchers designing similar studies in this area
of an acceptable design and the need for appropriate funding for resources to
recruit large enough consecutive samples of patients with solid tumour cancers.
The Utility of
Visual Inspection with Acetic Acid in Cervical Cancer
Screening
Author(s): Chidi
Okorie Onwuka, Ima-Obong A. Ekanem
Objective: Cervical cancer is potentially
preventable but still remains a leading cause of cancer mortality in in
developing countries like Nigeria. Cytology-based screening programmes are
difficult to maintain in these countries. Developing a cheap and reliable
alternative is an important public health measure in these regions. This study
was carried out to compare the utility of VIA and Pap smear as Cervical cancer screening methods in HIV-infected and non HIV-infected
women. Methodology: Between March, 2013 and March, 2014, 461
consenting women, comprising 231 HIV positive women (HPW) and 230 HIV negative
women (HNW) were recruited and screened for cervical cancer using conventional
Pap smear and VIA simultaneously in University of Uyo Teaching Hospital. The
Pap smear findings were classified using the 2001 Bethesda system. Patients
with a positive Pap smear or abnormal VIA findings were recalled for biopsy.
The results of the two tests were compared using biopsy as the gold
standard. Results: The overall sensitivity, specificity, positive
predictive value and negative predictive value for VIA were 100%,80%,76.9%, and
100%, respectively compared to 80%, 100%, 100%, and 88.2% for conventional Pap
smear. Visual inspection of the cervix with acetic acid for cervical cancer
screening is not specific but has a high negative predictive
value. Conclusion: This study does not support a “see-and-treat”
approach in cervical cancer management using VIA only. In resource-challenged
areas, VIA can be applied on a large scale basis in primary screening for
cervical cancer so as to triage, women who will benefit from further evaluation
before applying the appropriate treatment.
Immunotherapy
of Prostate Cancer Patients could Overexpress The Virulence
Factor Genes of E.faecalis
Author(s): Tayebe
Talebzade, Fahimeh Baghbani-arani, Soha Sadeghi, Arvin Haghighatfard, Niloofar
Ahmadi, Massoud Houshmand and Ali Dezhgir
Prostate cancer is the most prevalent
and second cause of death from cancer in men worldwide. Immunotherapy is a new
method for the treatment of several cancers that fights cancer cells by
strengthening the immune system through some medications. While immunotherapy is a useful method
for cancer treatment; its’ side effects still are not totally clarified.
Numbers of prostate cancer patients which take immunotherapy are
experiencing prostate
inflammation and prostatitis after treatment period. Enterococcus Faecalis is
Gram-positive and catalase-negative cocci that are common in the intestines of
humans and other animals and cause most enterococcal infections such as intestinal
infections, prostatitis, gastroenteritis and endocarditic. Present study aimed
to evaluate the mRNA level of virulence genes which are involved in
Enterococcus faecalis pathogenesis in prostate cancer patients that treated by
immunotherapy. Expression level of gelatinase E (gelE) and Enterococcal
surface protein (esp) genes were examined by Real time PCR in three groups of
68 male subjects. Group a normal subjects, group B prostate cancer patients
before start treatment and group C prostate cancer patients after six months
immunotherapy period. Results were showed significant (P<0.05) over
expression of both genes (gelEand esp) in group against the
group B. According to the results, it is reasonable that immunotherapy may have
side effects such as increasing the pathogenicity risk of microflora in
patients. Maybe these side effects could cause further infections after ending
the immunotherapy of cancer. Antibiotic usage after or at the same time of
immunotherapy period could prevent possible infections of microflora including
E. faecalis.